Loading...

PHAS - PhaseBio Pharmaceuticals, Inc.

Top Biomed Signal for 06-25-2022
Top Biomed Stock Signal: PHAS


Loading Chart PHAS

Stock Signal Information


Signal

Top Biomed Stock Signal: PHAS
Report Date: 06-25-2022
Symbol: PHAS - PhaseBio Pharmaceuticals, Inc.
Sector:
Industry:
Top Biomed Stock Signal: PHAS

  PHAS Technical Analysis

Company Contact

PhaseBio Pharmaceuticals, Inc. (PHAS)
1 Great Valley Pkwy Ste 30
Malvern, PENNSYLVANIA 19355
Phone: 16109816500
Website: http://phasebio.com
CEO: Mr. Jonathan Mow

PHAS, PhaseBio Pharmaceuticals, Inc.

PHAS PhaseBio Pharmaceuticals, Inc. Logo Image

NASDAQ, Nasdaq Global Select


Company Profile

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.